Lv2
196 积分 2020-11-02 加入
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
3天前
已完结
Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol
3天前
已完结
Cost–Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China
6天前
已完结
The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer
1个月前
已关闭
Rezvilutamide: First Approval
1个月前
已完结
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis
1个月前
已完结
关于高血压患者的血压控制目标值
1个月前
已完结
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
1个月前
已完结
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
1个月前
已完结
ARASAFE - a randomized, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m2 (in a 3-week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4-week cycle) in combination with Darolutamide + ADT in patients with mHSPC
1个月前
已完结
皖公网安备34019202002308
